ArticleFrontiers in pharmacology2017
Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy.
Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Synergy between photonics and biological approaches-A review of combination therapies for cancer theranostics.APL bioengineering · 2025Review
- Efficacy and safety of durvalumab + chemotherapyJournal of thoracic disease · 2023Article
- : A case report of re-challenge of immune checkpoint inhibitors after immune-related neurological adverse events: Review of literature.Medicine · 2022Review
- An immune cocktail therapy to realize multiple boosting of the cancer-immunity cycle by combination of drug/gene delivery nanoparticles.Science advances · 2020Article
- Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know).Journal of endocrinological investigation · 2019Review
- Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.Gynecologic oncology · 2018Review
Corrections and comments
- Erratum for
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
[This corrects the article on p. 49 in vol. 8, PMID: 28228726.].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.